Physician profile
Brandy Eling
NPI 1700487741
$3,255.69
in general payments reported to CMS, 2019-2025
35 companies · $1,730 in 2025
The $1,730 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $43.37 · 2022: $316 · 2023: $437 · 2024: $729 · 2025: $1,730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,342 · Education: $379 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,342.12 |
| Education | $378.97 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $640.77 | 2024-2025 | Xospata, Cresemba |
| Celgene Corporation | $304.51 | 2022-2025 | Reblozyl, Onureg |
| Abbvie INC. | $257.48 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $175.00 | 2025 | Ultomiris |
| Legend Biotech USA INC. | $172.91 | 2022-2024 | Carvykti |
| Pfizer INC. | $151.66 | 2023-2025 | |
| Blueprint Medicines Corporation | $146.36 | 2024 | Ayvakit |
| Beone Medicines USA, INC. | $131.32 | 2025 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $103.47 | 2022 | |
| Genzyme Corporation | $94.63 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $94.29 | 2023-2025 | |
| Incyte Corporation | $82.86 | 2024-2025 | Jakafi, Niktimvo, Monjuvi |
| Janssen Biotech, INC. | $79.45 | 2021-2024 | Talvey, Tecvayli, Imbruvica |
| Pharmacyclics LLC, An Abbvie Company | $69.51 | 2022-2023 | Imbruvica |
| Kyowa Kirin, INC. | $65.91 | 2023-2025 | Poteligeo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $64.87 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.20 | 2023-2025 | Livtencity, Iclusig |
| Genentech USA, INC. | $52.92 | 2023-2024 | Venclexta |
| Karyopharm Therapeutics INC. | $50.22 | 2023-2025 | Xpovio |
| Novartis Pharmaceuticals Corporation | $47.89 | 2023-2024 | |
| Daiichi Sankyo INC. | $46.79 | 2024-2025 | Vanflyta |
| Beigene USA, INC. | $45.19 | 2024-2025 | Brukinsa |
| Syndax Pharmaceuticals, INC. | $42.94 | 2025 | Revuforj |
| Adc Therapeutics America, INC. | $42.00 | 2022 | |
| Merck Sharp & Dohme LLC | $41.32 | 2023-2025 | Prevymis |
| Genmab U.S., INC. | $34.77 | 2024 | Epkinly |
| Sanofi-Aventis U.S. LLC | $28.65 | 2024 | |
| Glaxosmithkline, LLC. | $19.17 | 2025 | Ojjaara |
| Azurity Pharmaceuticals, INC. | $18.60 | 2025 | Danziten |
| Pharmacosmos Therapeutics INC. | $16.66 | 2025 | Monoferric |
| Nestle Healthcare Nutrition INC. | $15.80 | 2022 | |
| Servier Pharmaceuticals LLC | $15.54 | 2022 | |
| Taiho Oncology, INC. | $15.23 | 2023 | |
| Adaptive Biotechnologies Corporation | $14.00 | 2023 | Clonoseq |
| Pharming Healthcare, INC. | $12.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Eling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.